i
i
Up-to-date Information
Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-nCoV/index.html
Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021
-
January 7, 2022
-
Details:
-
Personal Author:
-
Corporate Authors:
-
Description:What is already known about this topic? SARS-CoV-2 infection is associated with worsening of diabetes symptoms, and persons with diabetes are at increased risk for severe COVID-19. SARS-CoV-2 infection might also induce newly diagnosed diabetes.
What is added by this report? Persons aged <18 years with COVID-19 were more likely to receive a new diabetes Diagnosis >30 days after infection than were those without COVID-19 and those with prepandemic acute respiratory infections. Non–SARS-CoV-2 respiratory infection was not associated with an increased risk for diabetes.
What are the implications for public health practice? The increased diabetes risk among persons aged <18 years following COVID-19 highlights the importance of COVID-19 Prevention strategies in this age group, including vaccination for all eligible persons and chronic disease Prevention and treatment.
The COVID-19 pandemic has disproportionately affected people with diabetes, who are at increased risk of severe COVID-19.* Increases in the number of type 1 diabetes diagnoses (1,2) and increased frequency and severity of diabetic ketoacidosis (DKA) at the time of diabetes Diagnosis (3) have been reported in European pediatric populations during the COVID-19 pandemic. In adults, diabetes might be a long-term consequence of SARS-CoV-2 infection (4–7). To evaluate the risk for any new diabetes Diagnosis (type 1, type 2, or other diabetes) >30 days† after acute infection with SARS-CoV-2 (the Virus that causes COVID-19), CDC estimated diabetes incidence among patients aged <18 years (patients) with diagnosed COVID-19 from retrospective cohorts constructed using IQVIA health care claims data from March 1, 2020, through February 26, 2021, and compared it with incidence among patients matched by age and sex 1) who did not receive a COVID-19 Diagnosis during the pandemic, or 2) who received a prepandemic non–COVID-19 acute respiratory infection (ARI) Diagnosis. Analyses were replicated using a second data source (HealthVerity; March 1, 2020–June 28, 2021) that included patients who had any health care encounter possibly related to COVID-19. Among these patients, diabetes incidence was significantly higher among those with COVID-19 than among those 1) without COVID-19 in both databases (IQVIA: hazard ratio [HR] = 2.66, 95% CI = 1.98–3.56; HealthVerity: HR = 1.31, 95% CI = 1.20–1.44) and 2) with non–COVID-19 ARI in the prepandemic period (IQVIA, HR = 2.16, 95% CI = 1.64–2.86). The observed increased risk for diabetes among persons aged <18 years who had COVID-19 highlights the importance of COVID-19 Prevention strategies, including vaccination, for all eligible persons in this age group,§ in addition to chronic disease Prevention and management. The mechanism of how SARS-CoV-2 might lead to incident diabetes is likely complex and could differ by type 1 and type 2 diabetes. Monitoring for long-term consequences, including signs of new diabetes, following SARS-CoV-2 infection is important in this age group
Suggested citation for this article: Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years — United States, March 1, 2020–June 28, 2021. MMWR Morb Mortal Wkly Rep. ePub: 7 January 2022.
mm7102e2.htm?s_cid=mm7102e2_w
mm7102e2-H.pdf
-
Subjects:
-
Series:
-
Document Type:
-
Place as Subject:
-
Pages in Document:7 numbered pages
-
Volume:71
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: